Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection
August 10, 2020 06:30 ET
|
Trevena Inc.
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 ...
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
July 30, 2019 07:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019
March 25, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Trevena Reports Fourth Quarter and Full Year 2018 Results
March 13, 2019 07:00 ET
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
March 11, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
January 28, 2019 07:00 ET
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
SPR Therapeutics Promotes Dr. Joseph Boggs to SVP of Research and Development
September 07, 2017 09:13 ET
|
SPR Therapeutics, LLC
CLEVELAND, Sept. 07, 2017 (GLOBE NEWSWIRE) -- SPR® Therapeutics, LLC (SPR), a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and...
Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery
August 03, 2017 11:03 ET
|
SPR Therapeutics, LLC
CLEVELAND, Ohio, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Patients in need of a total knee replacement (TKR) often delay surgery by two or more years because of concerns about the duration of postoperative...
SPR Therapeutics Appoints Michael P. Chuisano to Board of Directors
March 21, 2017 09:33 ET
|
SPR Therapeutics, LLC
CLEVELAND, March 21, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, LLC, a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and acute pain,...